ジペプチジルペプチダーゼ-4（DPP-4）阻害薬またはナトリウム-グルコース共輸送体2型（SGLT2）阻害薬の代謝および心血管系への影響

基本情報

NCT ID: NCT02528019
ステータス: 不明
試験のフェーズ: 第4相
試験タイプ: 介入
目標被験者数: 100
治験依頼者名: Kurume University

概要

Inhibition of dipeptidyl peptidase-4 (DPP-4) or sodium-glucose co-transporter type 2 (SGLT2) has been proposed as a therapeutic target for type 2 diabetes. However, how DPP-4 inhibitors or SGLT2 inhibitors exert protective actions for diabetic complications in addition to their glucose-lowering effects remains unknown.

対象疾患

Effects of the DPP-4 Inhibitors or SGLT2 Inhibitors on the Protective Actions for Diabetic Complications

介入

DPP-4 inhibiotors(DRUG)

SGLT2 inhibitors(DRUG)

Glimepiride(DRUG)

依頼者（Sponsor）

Kurume University(OTHER)

実施施設 (1)

久留米大学病院

Kurume, Japan(RECRUITING)